About CAP Global

CAP Global is a wholly owned subsidiary of Napo Pharmaceuticals. Napo is committed to the development and commercialization of novel, branded pharmaceuticals to global populations through the establishment of local partnerships.

CAP Global became a B Corp to allow Napo to embrace and communicate in a legal manner to our shareholders and other business partners the importance of considering the interests of all stakeholders when evaluating various strategic business opportunities.

Napo Pharmaceuticals is a privately held pharmaceutical company based in San Francisco, California. Napo's lead drug candidate, CROFELEMER, is under development for gastrointestinal indications, in persons living with HIV/AIDS. In addition to CROFELEMER, Napo has identified NP-500, a product for insulin-resistant diseases of Type II diabetes and Syndrome X. The company has a library of approximately 2,300 medicinal plants, all of which are available for screening for research and developmental purposes.

The Change We Seek™

CAP Global’s mission is to accelerate the development of CROFELEMER for pediatric populations in the treatment of multiple diarrheal diseases and to provide these drugs cost-effectively to relief organizations in the developing world. CROFELEMER is a novel pharmaceutical agent derived from raw plant material, which CAP Global sustainably harvests from rain forest areas. CAP Global employs fair trade work practices in all local businesses established to supply the plant material. They have a long-standing commitment to provide benefit sharing to all rain forest populations in recognition of their intellectual contribution to the study of medicinal plants.

• Napo is conducting a Phase 3 clinical trial (ADVENT) to evaluate the effectiveness and safety of a new therapy with the investigational agentCROFELEMER, for the treatment of diarrhea in patients with HIV infection.

• Napo and Direct Relief International ("DRI") of Santa Barbara, California have allied in a novel for- profit/not-for-profit effort to provide a development stage pharmaceutical product to pediatric populations in disaster situations and resource-constrained geographies, termed the Crofelemer Access Program ("CAP"). As part of the CAP, Napo has committed to sustainably provide CROFELEMER to DRI, for distribution to developing countries where cholera and other gastro-intestinal diseases are most prevalent.

CAP Global

• Industry: Biotechnology
• Product/Services: Chronic Diarrhea Medicines
• Location: South San Francisco, CA
• http://www.napopharma.com